ORBI-PHARMA INTERNATIONAL
ActiveORBI-PHARMA INTERNATIONAL has been active since 2008 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show negative equity (€-247k) and a net result of €-42k. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 5% of 8589 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.0% (low).
Checked score
Score 2025
Axes · tick = 2024
Profitability86▼-14
Solvency33=
Growth32=
Stability100
Bankruptcy probability, 12 months
1.0%
Low
0%0.5%1.5%4%10%≥ 25%
No credit on open account
Liquidity short (current ratio 0.36 against 0.4 in 2024), and equity is negative.
Credit advice for your own amount and term
Signals
Seven signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Annual accounts: weaker financial profile
The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
-152.9%
Return on assets
-26.2%
Age of the figures
15 mo
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 46
Relative position
BE, all sectors
reference
Sector 46
higher
← fewer bankruptcies
more bankruptcies →
raises risk · Negative equity
Equity is negative for financial year 2025: liabilities exceed assets. This is the trigger point of the alarm-bell procedure (Belgian CAC).
NBB · annual accounts 2025Equity per financial year
19202122232425
2019 to 2025 · latest year -€247k
neutral · Filed after the deadline
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 27-02-2026, 27 days later. For context: 47% of the Belgian market files late and the whole 1-to-90-day band measures 2.0% abnormal legal state against a 1.66% average. We show this as a fact and do not score it.
NBB · 10 filingsDeviation from the deadline
2025
27 d late
2024
27 d late
2023
16 d late
2022
4 d early
2021
4 d early
2020
3 d early
2019
7 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 30-06-2026 and is due by 31-01-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
30-06-2026 close15-09-2026 today31-01-2027 deadline
Financials · fiscal year 2025, abbreviated schema
Equity
€-247k▼ 20.7%
2024 · €-205k
2019: €-60k
2020: €-56k
2021: €-39k
2022: €944
2023: €-124k
2024: €-205k
2019 → 2025
Total assets
€162k▼ 8.8%
2024 · €177k
2019: €419k
2020: €445k
2021: €527k
2022: €460k
2023: €268k
2024: €177k
2019 → 2025
Net result
€-42k▲ 47.7%
2024 · €-81k
2019: €5k
2020: €4k
2021: €16k
2022: €40k
2023: €-125k
2024: €-81k
2019 → 2025
Working capital
€-261k▼ 14.1%
2024 · €-229k
2019: €-88k
2020: €-100k
2021: €-58k
2022: €-38k
2023: €-169k
2024: €-229k
2019 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€-39k-€944€-124k€-205k▼ 65.4%€-247k▼ 20.7%
Operating result€26k-€69k▲ 162%€-135k€-72k▲ 46.8%€-30k▲ 58.3%
Net result€16k-€40k▲ 145%€-125k€-81k▲ 35.1%€-42k▲ 47.7%
Turnover and EBIT margin not published: the abbreviated schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result stays negative: a loss of €30k in 2025 against €72k in 2024; the loss shrinks.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €162k
Fixed assets
€14k▼ 41.4%
Current assets
€147k▼ 3.7%
Key figures and ratios
EBITDA
€-17k▲
2024 · €-58k
Cash flow
€-29k▲
2024 · €-67k
Solvency
-152.9%▼
2024 · -115.6%
Current ratio
0.36▼
2024 · 0.40
Quick ratio
0.14▼
2024 · 0.15
Debt / equity
-1.65▲
2024 · -1.87
ROE
17.1%▼
2024 · 39.6%
ROA
-26.2%▲
2024 · -45.7%
Interest coverage
-1.69▲
2024 · -6.93
Debt
€409k▲
2024 · €382k
Debt ≤ 1 year
€409k▲
2024 · €382k
Income taxes
€3k▲
2024 · €686
Staff costs
€163k▼
2024 · €173k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€177k€162k▼
Fixed assets21/28€24k€14k▼
Tangible fixed assets22/27€24k€14k▼
Plant, machinery and equipment23€3k€2k▼
Furniture and vehicles24€17k€7k▼
Other tangible fixed assets26€4k€5k▲
Current assets29/58€153k€147k▼
Stocks and contracts in progress3€97k€92k▼
Stocks30/36€42k€50k▲
Contracts in progress37€55k€43k▼
Amounts receivable within one year40/41€48k€41k▼
Trade receivables40€47k€41k▼
Other amounts receivable41€380€422▲
Cash at bank and in hand54/58€3k€1k▼
Deferred charges and accrued income490/1€6k€13k▲
Equity and liabilities
Total equity and liabilities10/49€177k€162k▼
Equity10/15€-205k€-247k▼
Contributions10/11€12k€12k=
Reserves13€2k€2k=
Non-distributable reserves130/1€2k€2k=
Reserves not available under the articles1311€2k€2k=
Profit (loss) carried forward14€-219k€-262k▼
Amounts payable17/49€382k€409k▲
Amounts payable within one year42/48€382k€409k▲
Current portion of amounts payable after more than one year42€13k-
Financial debts43€100k€100k▲
Credit institutions430/8€100k€100k▲
Trade debts44€176k€184k▲
Suppliers440/4€176k€184k▲
Taxes, remuneration and social security45€73k€69k▼
Taxes450/3€44k€44k▼
Remuneration and social security454/9€29k€26k▼
Other amounts payable47/48€21k€56k▲
Income statement
Code20242025
Non-recurring operating income76A€7k€6k▼
Remuneration, social security and pensions62€173k€163k▼
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630€14k€13k▼
Other operating charges640/8€5k€2k▼
Non-recurring operating charges66A€4k-
Gross operating margin9900€124k€148k▲
Operating profit (loss)9901€-72k€-30k▲
Financial income75/76B€393€27▼
Recurring financial income75€393€27▼
Financial charges65/66B€9k€10k▲
Recurring financial charges65€8k€10k▲
Non-recurring financial charges66B€500-
Profit (loss) for the period before taxes9903€-80k€-40k▲
Income taxes67/77€686€3k▲
Profit (loss) for the period9904€-81k€-42k▲
Profit (loss) for the period to be appropriated9905€-81k€-42k▲
Appropriation of the result
Profit (loss) to be appropriated9906€-219k€-262k▼
Profit (loss) brought forward from the previous period14P€-138k€-219k▼
Social balance
Average headcount (FTE)90872.6-
The notes to these accounts (9 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
27-02
NBB filing
Annual accounts filed
fiscal year 2025 · abbreviated schema · 27 days late
2025
27-02
NBB filing
Annual accounts filed
fiscal year 2024 · abbreviated schema · 27 days late
2024
16-02
NBB filing
Annual accounts filed
fiscal year 2023 · abbreviated schema · 16 days late
2023
30-06
Financial
Weakest financial yearnet €-125k ▼409%
Net result drops to €-125k, the lowest in the series; recovery starts the following year.
27-01
NBB filing
Annual accounts filed
fiscal year 2022 · abbreviated schema
2022
30-06
Financial
Highest result since 2019net €40k ▲145%
Operating result €69k, net result €40k, both a record.
27-01
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
28-01
NBB filing
Annual accounts filed
fiscal year 2020 · abbreviated schema
2020
24-01
NBB filing
Annual accounts filed
fiscal year 2019 · abbreviated schema
2018
13-12
NBB filing
Annual accounts filed
fiscal year 2018 · abbreviated schema
2017
21-12
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2016
23-12
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
no sitting director, no change since 2010
We have established no sitting directors for this company. We derive directors from published Gazette acts; while there are none, or none read, nothing appears here. That does not mean the company has none: the CBE keeps its own list of function holders, which we do not read.
26-11-2010
Resigned as Manager
Location & real-estate footprint
Registered office, Bierbeek · 1 establishment unit since 2008
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Dorpsstraat 173360 BierbeekGround area
483 m²
Building footprint
107 m²
Volume, LiDAR
689 m³
Parcel 24011D0294/00B000, Flanders · tallest building 11.2 m, ±2 floors. Linked by address, not a title deed.
1 establishment unit
ORBI-PHARMA INTERNATIONAL
since 20082.172.140.103
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 24011D0294/00B000 | Flanders | 483 m² | 1 · 107 m² | 11.2 m · 2 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Public money · subsidies and aid
Flemish government
2022 to 2023 · 2 entries · 3,553 EUR awarded · 3,553 EUR paid| Year | Entries | awarded | paid |
|---|---|---|---|
| 2023 | 1 | 1,730 EUR | 1,730 EUR |
| 2022 | 1 | 1,823 EUR | 1,823 EUR |
Schemes
Subsidies voor internationaal ondernemen
Similar companies · same sector, comparable size
NOVALAB
BE 1022.235.092
Ukkel · Eq €925
Vivre au Sud
BE 0760.364.093
Incourt · Eq €876
O CARE PHARMA
BE 0732.714.046
Hasselt · Eq €1k
ARBILUX
BE 0419.806.595
Durbuy · Eq €1k
Kolibrie Veterinair Distributiecentrum
BE 1002.235.870
Beringen · Eq €1k
Of 1,894 companies in sector 46460 we hold annual accounts for 1,114. 40 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company
Founded23-07-2008
Fiscal year end30-06
Activities, NACEBEL
46460Wholesale of pharmaceutical and medical goods
70200Business and other management consultancy
70220Business consulting
82990Other business support services
96999Other personal services
Sources
Crossroads Bank for EnterprisesNational Bank · 16 filingsAddress and cadastre registers
Data from official sources, last processed on 15-09-2026. Scores and ratios are computed by Checked and are not a credit decision.
Contact details
2 entriesE-mail:alain.swinnen@skynet.be
Phone:0476/318644